Uranium Energy Corp. (UEC) Income Statement

The company swung from $49.8M in revenue (2025Q2) to zero for three consecutive quarters, then recorded $20.2M in 2026Q2 and $17.1M in 2026Q4. This pattern is inconsistent with a scaling ISR producer generating recurring sales and instead appears to reflect opportunistic physical uranium disposals timed to spot price movements. The reported TTM revenue of approximately $66.8M is heavily concentrated in a single quarter (2025Q2), making the trailing figure a poor proxy for ongoing earning power. Investors should monitor whether subsequent quarters show sustained, multi-quarter revenue recognition rather than isolated sales events.

The shift from a 36.6% gross margin (2025Q1-Q2) to deeply negative margins in 2026Q2 (-76.0%) and 2026Q4 (-173.4%) is the most concerning trend in the income statement. The -173.4% figure implies that for every dollar of revenue recognized, the company incurred approximately $2.73 in direct costs, which may reflect the capitalization and subsequent expensing of wellfield development costs, chemical reagent consumption, or standby facility maintenance that is not proportionally linked to sales volume. This dynamic warrants close scrutiny because it suggests UEC's ISR operations are not yet achieving the low-cost profile that the hub-and-spoke model is theoretically designed to deliver. If this margin profile persists as production volumes increase, the economic thesis around ISR as a structurally lower-cost extraction method would need to be revisited.

SG&A expenses have fluctuated between $5.3M and $13.3M over the period, with the most recent four quarters averaging approximately $8.6M. However, even in the strongest revenue quarter (2025Q2, $49.8M), operating income remained negative at -$3.6M, and losses have since widened materially despite comparable revenue in other quarters. This pattern suggests that incremental revenue is not translating into incremental operating income, which would typically indicate that variable costs—likely wellfield reagents, water handling, and royalty obligations—are scaling proportionally or faster than sales. The operating leverage thesis, which underpins the ISR cost-advantage argument, remains unvalidated based on these figures, and the company's -109.7% TTM operating margin confirms that overhead absorption is not yet materializing.

The SBC trajectory is notable because it appears to be growing independent of operational scale, rising even in quarters with zero reported revenue. At $6.0M in 2026Q4, SBC alone accounts for roughly 64% of that quarter's $9.6M SG&A expense, suggesting that a significant and growing portion of the company's overhead is non-cash but dilutive. Meanwhile, the zero R&D line across all ten quarters indicates that UEC does not capitalize the exploration and evaluation expenditures in the same way peers might, which may make the SG&A line appear cleaner than peers while shifting cost recognition to other balance sheet accounts. Given the company's stated $148.9M cash position and its consistent equity-funded capital structure, the pace of SBC accretion warrants monitoring as a potential precursor to further share count expansion beyond the current warrant overhang.